Growth Hormone Peptides: A Researcher's Guide

Growth hormone secretagogues operate through a fundamentally different pathway than direct hormone replacement: instead of introducing synthetic GH, they hijack the body's own pulsatile release machinery through the ghrelin receptor. This distinction matters not just pharmacologically, but practically — these compounds trigger endogenous GH secretion patterns that preserve feedback regulation, at least in theory. The most studied members of this class show remarkably different half-lives, receptor selectivity profiles, and secondary endocrine effects despite acting on the same receptor system.

The GHS-R1a Pathway: What Makes a Growth Hormone Secretagogue

All compounds in this category target the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed primarily in the anterior pituitary and hypothalamus. GHS-R1a is the endogenous receptor for ghrelin, the 28-amino-acid "hunger hormone" that signals energy deficit and stimulates GH release. Growth hormone secretagogues bind this same receptor, mimicking ghrelin's GH-releasing effect without necessarily triggering appetite.

When a secretagogue activates GHS-R1a in somatotroph cells of the anterior pituitary, it initiates a signaling cascade through Gq/11 proteins. This cascade mobilizes intracellular calcium stores and activates protein kinase C, ultimately triggering the exocytosis of growth hormone-containing vesicles. The released GH then circulates to the liver and peripheral tissues, where it stimulates insulin-like growth factor 1 (IGF-1) production — the mediator of most growth hormone effects.

The critical mechanistic distinction from exogenous GH administration is pulsatility. Endogenous growth hormone is released in discrete pulses, primarily during sleep, with trough periods in between. These pulses preserve the downregulation patterns that prevent receptor desensitization. Secretagogues maintain this pulsatile pattern because they amplify existing GH release machinery rather than bypassing it. Whether this theoretical advantage translates to clinical benefit remains an open question given the limited long-term human data.

Structural Distinctions Within the Secretagogue Class

The growth hormone secretagogue category splits into peptide and non-peptide subclasses, with significant pharmacological differences between individual compounds even within the peptide group.

Peptide secretagogues vary substantially in half-life and selectivity. Sermorelin, a 29-amino-acid fragment of growth hormone-releasing hormone (GHRH), acts through a different receptor entirely — the GHRH receptor rather than GHS-R1a. It has a plasma half-life under 10 minutes, requiring multiple daily injections and offering minimal overlap with the ghrelin receptor system. Ipamorelin, a pentapeptide, binds GHS-R1a with high selectivity and minimal spillover to cortisol or prolactin release, a profile demonstrated in multiple rodent and limited human studies. Its half-life is approximately 2 hours, allowing once or twice-daily dosing.

CJC-1295 DAC represents a different design strategy: it is a GHRH analog that includes a drug affinity complex (DAC) modification, extending its half-life to roughly one week through albumin binding. This modification transforms pulsatile release into sustained elevation, which may undermine the very feedback mechanisms that distinguish secretagogues from exogenous GH. The trade name refers to the DAC variant specifically; Mod GRF 1-29 is the non-DAC version with a half-life similar to sermorelin but greater enzymatic stability.

GHRP-2, GHRP-6, and Hexarelin are earlier-generation GHS-R1a agonists. GHRP-6 was among the first to demonstrate GH release in humans, but it also stimulates appetite and cortisol release at effective doses. GHRP-2 shows slightly better selectivity. Hexarelin, the most potent of the three, has been studied in cardiac applications beyond GH release, but it also produces the strongest cortisol response.

Tesamorelin is the only FDA-approved GHRH analog, cleared specifically for HIV-associated lipodystrophy. It is essentially a stabilized form of GHRH with a trans-3-hexenoyl group attached, extending half-life modestly while maintaining GHRH receptor selectivity. Its approval was based on Phase III data showing visceral adipose tissue reduction, making it the sole member of this category with formal regulatory clearance for any indication.

The non-peptide outlier is MK-677 (ibutamoren), an orally active small molecule that binds GHS-R1a. Its oral bioavailability and 24-hour half-life distinguish it from injectable peptides. MK-677 has been studied in multiple Phase II trials for conditions including frailty, growth hormone deficiency, and osteoporosis. It reliably raises GH and IGF-1 in a dose-dependent manner, but it also increases appetite, fluid retention, and fasting glucose in a subset of users — effects tied to its ghrelin receptor agonism.

The Evidence Landscape: Where Human Data Exist and Where They Don't

The evidence base for growth hormone secretagogues is sharply stratified. A handful of compounds have controlled human data; most do not.

Tesamorelin has the strongest human evidence: two Phase III trials (LIPODYSTROPHY-I and II) enrolled over 800 HIV-positive patients with central fat accumulation and demonstrated significant reductions in visceral adipose tissue compared to placebo, measured by CT imaging. These trials ran for 26 weeks with open-label extensions, providing relatively long-term safety data in a specific population. Tesamorelin's approval was based on this evidence, but its generalizability to other populations is uncertain.

MK-677 has been studied in multiple controlled human trials. A 1999 study in elderly adults showed sustained increases in GH and IGF-1 over two years, with modest increases in lean mass but no improvement in functional capacity. A 2008 trial in patients with hip fracture found no benefit on recovery outcomes. A small 2015 trial reported one case of acute hepatotoxicity, raising unresolved safety questions. Despite this body of work, MK-677 is not approved for any indication, and its long-term metabolic effects remain incompletely characterized.

Sermorelin was once available as an FDA-approved diagnostic agent (Geref), but it was withdrawn from the U.S. market in 2008 for commercial reasons, not safety concerns. Clinical trials in growth hormone-deficient children showed efficacy in promoting linear growth, but data in adults are sparse.

Ipamorelin has limited published human data. Early Phase I studies demonstrated dose-dependent GH release with minimal cortisol or prolactin elevation, but no Phase II or Phase III trials have been published. Most evidence comes from rodent studies and unpublished clinical use.

CJC-1295 DAC appeared in one small human trial (2006, 30 subjects) showing sustained IGF-1 elevation over two weeks after a single injection. No follow-up studies or long-term safety data have been published. Mod GRF 1-29 has even less human evidence, with most data derived from in vitro receptor binding studies and animal models.

GHRP-2, GHRP-6, and Hexarelin have scattered human pharmacokinetic studies from the 1990s demonstrating GH release, but no large-scale efficacy trials. Hexarelin's cardiac effects — including desensitization of the GH response after repeated dosing — were documented in small human studies but have not been systematically followed up.

The gap between rodent studies and human outcomes is substantial across this category. Rodent models consistently show GH and IGF-1 elevation, increased lean mass, and improved bone density, but translating these findings to human metabolic and functional outcomes has proven difficult. The compounds for research purposes only outside of tesamorelin's narrow indication.

Compounds in This Category

Sermorelin is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous peptide that stimulates pituitary GH release. Unlike GHS-R1a agonists, sermorelin binds the GHRH receptor, making it mechanistically distinct within this category. Its extremely short half-life limits practical utility, but it has historical significance as one of the first peptide-based approaches to GH stimulation and was used diagnostically before its withdrawal from the U.S. market.

Ipamorelin is a pentapeptide GHS-R1a agonist notable for its high selectivity — it stimulates GH release without significantly raising cortisol, prolactin, or ACTH at effective doses. Early human studies confirmed its GH-releasing activity, but controlled efficacy data in clinical endpoints remain absent. Rodent studies show favorable body composition effects, but human translation of these findings has not been rigorously tested in peer-reviewed trials.

MK-677 is the only orally bioavailable secretagogue in this category, a non-peptide compound with a 24-hour half-life. It has the most extensive human safety data after tesamorelin, including two-year studies in elderly populations. These trials demonstrated sustained GH and IGF-1 elevation but modest and inconsistent effects on lean mass, functional capacity, and bone density, with notable side effects including appetite stimulation, edema, and elevated fasting glucose in some subjects.

CJC-1295 DAC is a GHRH analog modified with a drug affinity complex to extend its half-life to roughly one week through albumin binding. This modification produces sustained rather than pulsatile GH elevation, which may disrupt normal feedback regulation. Human data are limited to one small pharmacokinetic study; no controlled efficacy trials exist.

Mod GRF 1-29 is a GHRH analog without the DAC modification, retaining a short half-life similar to sermorelin but with improved enzymatic stability due to amino acid substitutions. It is essentially the active core of CJC-1295 DAC without the albumin-binding tail. Human data are minimal, with most evidence coming from rodent studies demonstrating GH release.

GHRP-2 and GHRP-6 are hexapeptide GHS-R1a agonists from the first generation of synthetic secretagogues. Both stimulate GH release in humans, but GHRP-6 also triggers appetite and cortisol elevation at effective doses. GHRP-2 shows slightly better selectivity. Neither has been studied in controlled efficacy trials beyond small pharmacokinetic investigations from the 1990s.

Hexarelin is the most potent of the GHRP series but also produces the strongest cortisol response. It has been studied for cardiac effects beyond GH release, including direct cardioprotective activity in animal models, though human cardiac data are limited. Repeated dosing leads to desensitization of the GH response, a phenomenon documented in small human studies.

Tesamorelin is a stabilized GHRH analog with a trans-3-hexenoyl group that modestly extends its half-life. It is the only FDA-approved compound in this category, cleared for reducing excess abdominal fat in HIV-positive patients with lipodystrophy. Two Phase III trials demonstrated significant reductions in visceral adipose tissue measured by CT, making it the sole secretagogue with regulatory backing for a specific indication.

FAQ

Q: What distinguishes growth hormone secretagogues from direct GH administration?

Secretagogues amplify the body's endogenous GH release through the ghrelin receptor or GHRH receptor, preserving pulsatile secretion patterns and feedback regulation. Direct GH administration delivers synthetic hormone continuously, bypassing the pituitary entirely and suppressing endogenous GH production through negative feedback. Whether the preserved pulsatility of secretagogues offers clinical advantages over exogenous GH is unresolved due to limited head-to-head human data.

Q: Why do some secretagogues raise cortisol and others don't?

Receptor selectivity determines secondary endocrine effects. GHRP-6 and hexarelin bind GHS-R1a but also activate receptors or pathways that trigger ACTH release from the pituitary, leading to cortisol elevation. Ipamorelin shows high GHS-R1a selectivity with minimal ACTH cross-reactivity in both animal models and limited human studies. MK-677 does not significantly raise cortisol at therapeutic doses, though appetite stimulation is common due to its ghrelin receptor agonism.

Q: What is the strongest human evidence for clinical benefit in this category?

Tesamorelin's two Phase III trials in HIV-associated lipodystrophy are the only large-scale controlled studies demonstrating a clinically meaningful outcome — visceral fat reduction — in humans. MK-677 has the most extensive human safety data, including two-year trials, but these studies showed minimal functional benefit despite sustained GH and IGF-1 elevation. For all other compounds in this category, human efficacy data are either absent or limited to small pharmacokinetic studies.

Q: Do peptide secretagogues require refrigeration?

Most peptides in this category are supplied as lyophilized powder and remain stable at room temperature in this form for extended periods. Once reconstituted with bacteriostatic water, they require refrigeration at 2-8°C and should be used within several weeks. MK-677, being a non-peptide small molecule, is typically provided as a powder or solution that does not require refrigeration, though storage recommendations vary by supplier.

Q: Can secretagogues be used long-term without losing effectiveness?

Hexarelin shows documented desensitization of the GH response after repeated dosing in human studies, a phenomenon tied to receptor downregulation. MK-677 maintained GH and IGF-1 elevation over two years in elderly subjects without apparent tachyphylaxis, though functional benefits were modest. For ipamorelin, GHRP-2, and the GHRH analogs, long-term human data on desensitization do not exist. Rodent studies suggest tolerance may develop with continuous dosing, but pulsatile administration may preserve responsiveness.

This article is for informational and research purposes only. These compounds are not approved for human use outside tesamorelin's specific FDA-cleared indication, and their safety and efficacy in other contexts have not been established through adequate clinical trials. Consult a qualified healthcare provider before considering any growth hormone secretagogue for research or clinical investigation.